Cipla Ltd. News and Updates

Name: Latest research reports of Cipla Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

21 Apr 2025

1499.70

1.06%

Cipla and CanSupport take free palliative care services to more homes in Pune

Business Line

With nine dedicated home care teams, the initiative will provide supportive care to more than 900 cancer patients, making it the largest home-based palliative care service in Maharashtra'

Cipla Ltd. is trading below its 200 day SMA of 1509.3

Cipla Ltd.

11 Apr 2025

1499.70

1.06%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Cipla Ltd. is trading below its 200 day SMA of 1509.3

Cipla gets USFDA nod for generic cancer drug

Business Line | 11 Apr 2025 1 more

Cipla Ltd.

11 Apr 2025

1499.70

1.06%

Cipla (CIPLA IN) Event Update Gets approval for...

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla Ltd.

22 Mar 2025

1499.70

1.06%

Cipla: Better positioned to grow and deal with tariff uncertainties

Business Line

All segments on strong footing to deliver long-term growth

Cipla Ltd. is trading below its 200 day SMA of 1509.3

Cipla Ltd.

18 Mar 2025

1499.70

1.06%

Cipla Secures Exclusive Licensing For Innovative Ophthalmic Solution

NDTV Profit

Under the agreement, Cipla gains exclusive rights to market this innovative treatment for post-operative inflammation and pain.

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Ltd.

28 Feb 2025

1499.70

1.06%

Tariffs should not determine how Indian drugmakers operate: Cipla CEO

Business Standard

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of popular drugs

Cipla Ltd. is trading above its 150 day SMA of 1479.1

Cipla Ltd.

07 Feb 2025

1499.70

1.06%

Cipla stock shows strength on charts, adopt Bull Spread: Nandish Shah

Business Standard

Cipla share price: The short-term trend turned positive as Cipla stock price closed above its 5 and 11 day EMA

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla Ltd.

03 Feb 2025

1499.70

1.06%

Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure

NDTV Profit

Cipla Medpro is responsible for the manufacturing, marketing, and supply of pharmaceutical products in South Africa.

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla Ltd.

29 Jan 2025

1499.70

1.06%

Cipla Q3 Results 2025 on 29 Jan, 2025: profit rise by 48.74% YOY, profit at 1570.51 crore and revenue at 7072.97 crore

livemint

Cipla Q3 Results 2025 on 29 Jan, 2025: Revenue increased by 7.1% YoY & profit increased by 48.74% YoY, profit at 1570.51 crore and revenue at 7072.97 crore